Inhibiting protein aggregation with nanomaterials: The underlying mechanisms and impact factors

• Published in: Biochimica et biophysica acta. General subjects Vol. 1866; no. 2; p. 130061
• Main Authors: Wang, Shilin, Zheng, Jiaojiao, Ma, Liang, Petersen, Robert B., Xu, Li, Huang, Kun
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.02.2022
• Subjects: Amyloid; Amyloidogenic Proteins - chemistry; Amyloidogenic Proteins - metabolism; Animals; Humans; Impact factors; Mechanism; Nanomaterials; Nanostructures - chemistry; Protein Aggregates; Protein Aggregation, Pathological - metabolism; protein folding; Protein misfolding diseases; Proteostasis Deficiencies - drug therapy; Proteostasis Deficiencies - metabolism; Proteostasis Deficiencies - pathology; therapeutics; toxicity; HI; T2DM; BBB; TDP 43; BI; ALS; HTT; PMDs; Mechanism; Aβ; BSA; PTT; SPR; FTIR; α-Syn; HSA; MD; β-lg; Amyloid; hIAPP; CD; AD; TSE; Impact factors; Nanomaterials; HEWL; PD; NIR; HD; PTA; Protein misfolding diseases; TEM; ThS
• ISSN: 0304-4165; 1872-8006; 1872-8006
• DOI: 10.1016/j.bbagen.2021.130061

Protein aggregation is correlated with the onset and progression of protein misfolding diseases (PMDs). Inhibiting the generation of toxic aggregates of misfolded proteins has been proposed as a therapeutic approach for PMDs. Due to their unique properties, nanomaterials have been extensively investigated for their ability to inhibit protein aggregation and have shown great potential in the diagnosis and treatment of PMDs. However, the precise mechanisms by which nanomaterials interact with amyloidogenic proteins and the factors influencing these interactions remain poorly understood. Consequently, developing a rational design strategy for nanomaterials that target specific proteins in PMDs has been challenging. In this review, we elucidate the effects of nanomaterials on protein aggregation and describe the mechanisms through which nanomaterials interfere with protein aggregation. The major factors impacting protein-nanomaterial interaction such as size, charge, concentration, surface modification and morphology that can be rationally addressed to achieve the desired effects of nanomaterials on protein aggregation are summarized. The prospects and challenges to the clinical application of nanomaterials for the treatment of PMDs are also discussed.